Roche confirms patient death in ACE910 PhIII hemophilia trial, spurring new questions about top blockbuster hopeful
Just a few months after reporting a slate of serious adverse events for its pivotal Phase III study of emicizumab (ACE910) for hemophilia, Roche has raised fresh questions about the safety of the drug following the death of one of the patients in the trial.
In a statement given to the European Haemophilia Association, Roche says that the patient in their HAVEN-1 study died following two serious adverse events.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.